top of page

SUBSCRIBE TO OUR NEWSLETTER

THE FASTER WE MOVE

Search

New collaboration between MEDSIR and Dana Farber

MedSIR
Nov 7, 2022
1 min read

Updated: Jul 26, 2023

MEDSIR'S MENTIONS

SPAIN

Infosalus - Estudian el papel del microbioma como nuevo biomarcador de respuesta a la inmunoterapia en cáncer de mama
Farmabiotec - MEDSIR y el Instituto del Cáncer Dana-Farber se alían para investigar un nuevo biomarcador de respuesta a la inmunoterapia en cáncer de mama

Recent Posts

New potential treatment strategy for brain metastases and leptomeningeal disease: HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

New potential treatment strategy for brain metastases and leptomeningeal disease: HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

From Barcelona to Boston: MEDSIR Celebrates 13 Years Advancing Global Cancer Research Through Innovation and international Collaboration

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

MEDSIR & Debiopharm Announce the First Patient Dosed in the WIN-B Trial Exploring the Combination of Debio 0123 & Gileads Trodelvy® in Advanced Breast Cancer

Comments

GET OUR MONTHLY NEWSLETTER!

bottom of page